GILEAD SCIENCES, INC. vs Merck & Co., Inc., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where GILD and MRK diverge most: on ev/ebitda, GILD reads 17.4 and MRK reads 629.4; on return on assets, GILD reads 16.4% and MRK reads 6.9%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | GILD | MRK |
|---|---|---|
| Price | $130.19 | $130.21 |
| Market cap | $163.3B | $321.9B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +11.4% |
| P/E | 17.7 | 36.7 |
| P/B | 6.94 | 7.01 |
| P/S | 5.49 | 4.89 |
| EV/EBITDA | 17.4 | 629.4 |
| Revenue growth | +3.5% | +2.9% |
| Operating margin | 37.2% | — |
| Net margin | 31.0% | 13.6% |
| Return on equity | 39.2% | 19.4% |
| Return on assets | 16.4% | 6.9% |
| Return on invested capital | 17.3% | — |
| FCF yield | 6.3% | 4.4% |
| Dividend yield | 2.4% | 2.5% |
| Debt / equity | 1.00 | 1.07 |
| Current ratio | 1.97 | 1.30 |
| Altman Z (solvency) | 7.23 | 7.31 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.